Interactions of everolimus and sorafenib in pancreatic cancer cells

AAPS Journal

Volumn 15, Issue 1, 2013, Pages 78-84

  Pawaskar, Dipti K ^a   Straubinger, Robert M ^a,b   Fetterly, Gerald J ^b   Ma, Wen W ^b   Jusko, William J ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

everolimus; MiaPaCa 2; modeling interactions; Panc 1; sorafenib

Indexed keywords

EVEROLIMUS; SORAFENIB;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENCY; IC 50; IN VITRO STUDY; PANCREAS CANCER;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG INTERACTIONS; HUMANS; NIACINAMIDE; PANCREATIC NEOPLASMS; PHENYLUREA COMPOUNDS; SIROLIMUS;

EID: 84871944412     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-012-9417-7     Document Type: Article

References (37)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212-36. Epub 2011/06/21.
2. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25(15):1960-6. Epub 2007/04/25. (Pubitemid 46972777)
3. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321(5897):1801-6. Epub 2008/09/06.
4. Maitra A, Hruban RH. Pancreatic cancer. Annu Rev Pathol. 2008;3:157-88. Epub 2007/11/28. (Pubitemid 351488279)
5. Beeram M, Patnaik A, Rowinsky EK. Raf: a strategic target for therapeutic development against cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(27):6771-90. Epub 2005/09/20. (Pubitemid 46194105)
6. Altomare DA, Tanno S, De Rienzo A, Klein-Szanto AJ, Skele KL, Hoffman JP, et al. Frequent activation of AKT2 kinase in human pancreatic carcinomas. J Cell Biochem. 2002;87(4):470-6. Epub 2004/01/23.
7. Cheng JQ, Ruggeri B, Klein WM, Sonoda G, Altomare DA, Watson DK, et al. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci U S A. 1996;93(8):3636-41. Epub 1996/04/16. (Pubitemid 26127592)
8. Ruggeri BA, Huang L, Wood M, Cheng JQ, Testa JR. Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Mol Carcinog. 1998;21(2):81-6. Epub 1998/03/13. (Pubitemid 28122842)
9. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2(7):489-501. Epub 2002/07/03. (Pubitemid 37328931)
10. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 2008;7(10):3129-40. Epub 2008/10/15.
11. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64(19):7099-109. Epub 2004/10/07. (Pubitemid 39331023)
12. Ulivi P, Arienti C, Amadori D, Fabbri F, Carloni S, Tesei A, et al. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines. J Cell Physiol. 2009;220(1):214-21. Epub 2009/03/17.
13. Lane HA, Wood JM, McSheehy PM, Allegrini PR, Boulay A, Brueggen J, et al. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res. 2009;15(5):1612-22. Epub 2009/02/19.
14. Mabuchi S, Altomare DA, Connolly DC, Klein-Szanto A, Litwin S, Hoelzle MK, et al. RAD001 (everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res. 2007;67(6):2408-13. Epub 2007/03/17. (Pubitemid 46548923)
15. Boulay A, Zumstein-Mecker S, Stephan C, Beuvink I, Zilbermann F, Haller R, et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res. 2004;64(1):252-61. Epub 2004/01/20. (Pubitemid 38114106)
16. Stracke S, Ramudo L, Keller F, Henne-Bruns D, Mayer JM. Antiproliferative and overadditive effects of everolimus and mycophenolate mofetil in pancreas and lung cancer cells in vitro. Transplant Proc. 2006;38(3):766-70. Epub 2006/05/02.
17. Campbell M, Allen WE, Sawyer C, Vanhaesebroeck B, Trimble ER. Glucose-potentiated chemotaxis in human vascular smooth muscle is dependent on cross-talk between the PI3K and MAPK signaling pathways. Circ Res. 2004;95(4):380-8. Epub 2004/07/10. (Pubitemid 39100456)
18. Hausenloy DJ, Mocanu MM, Yellon DM. Cross-talk between the survival kinases during early reperfusion: its contribution to ischemic preconditioning. Cardiovasc Res. 2004;63(2):305-12. Epub 2004/07/14. (Pubitemid 38900844)
19. Naegele S, Morley SJ. Molecular cross-talk between MEK1/2 and mTOR signaling during recovery of 293 cells from hypertonic stress. J Biol Chem. 2004;279(44):46023-34. Epub 2004/08/05. (Pubitemid 39491596)
20. Lasithiotakis KG, Sinnberg TW, Schittek B, Flaherty KT, Kulms D, Maczey E, et al. Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells. J Investig Dermatol. 2008;128(8):2013-23. Epub 2008/03/08. (Pubitemid 352001225)
21. Molhoek KR, Brautigan DL, Slingluff Jr CL. Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor rapamycin. J Transl Med. 2005;3:39. Epub 2005/11/01. (Pubitemid 41631821)
22. Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B, Cabellos L, et al. Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol. 2009;51(4):725-33. Epub 2009/08/12.
23. Ramakrishnan V, Timm M, Haug JL, Kimlinger TK, Halling T, Wellik LE, et al. Sorafenib, a multikinase inhibitor, is effective in vitro against non-hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin. Am J Hematol. 2012;87(3):277-83. Epub 2011/12/23.
24. Fraser TR. Lecture on the antagonism between the actions of active substances. Br Med J. 1872;2(618):485-7. Epub 1872/11/02.
25. Zhao L, Wientjes MG, Au JL. Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin Cancer Res. 2004;10(23):7994-8004. Epub 2004/12/09. (Pubitemid 39587541)
26. Greco WR, Bravo G, Parsons JC. The search for synergy: a critical review from a response surface perspective. Pharmacol Rev. 1995;47(2):331-85. Epub 1995/06/01.
27. Gaddum JH. The quantitative effects of antagonistic drugs. J Physiol. 1937;89:7P.
28. Ariens EJ, Van Rossum JM, Simonis AM. Affinity, intrinsic activity and drug interactions. Pharmacol Rev. 1957;9(2):218-36. Epub 1957/06/01.
29. Chakraborty A, Jusko WJ. Pharmacodynamic interaction of recombinant human interleukin-10 and prednisolone using in vitro whole blood lymphocyte proliferation. J Pharm Sci. 2002;91(5):1334-42. Epub 2002/04/27. (Pubitemid 34651195)
30. Earp J, Krzyzanski W, Chakraborty A, Zamacona MK, Jusko WJ. Assessment of drug interactions relevant to pharmacodynamic indirect response models. J Pharmacokinet Pharmacodyn. 2004;31(5):345-80. Epub 2005/01/27. (Pubitemid 39620007)
31. Ariens EJ. Molecular basis of drug action. Med Arh. 1964;18:21-38. Epub 1964/08/01. Molekulska osnova djelovanja lijekova.
32. Ariens EJ, Simonis AM. A molecular basis for drug action. The interaction of one or more drugs with different receptors. J Pharm Pharmacol. 1964;16:289-312. Epub 1964/05/01.
33. D'Argrnio DZ, Schumitzky A, Wang X. ADAPT 5 user's guide: pharmacokinetic/pharmacodynamic systems analysis software. 2009.
34. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest. 2008;118(9):3065-74. Epub 2008/08/30.
35. Zhao L, Au JL, Wientjes MG. Comparison of methods for evaluating drug-drug interaction. Front Biosci (Elite Ed). 2010;2:241-9. Epub 2009/12/29.
36. Deer EL, Gonzalez-Hernandez J, Coursen JD, Shea JE, Ngatia J, Scaife CL, et al. Phenotype and genotype of pancreatic cancer cell lines. Pancreas. 2010;39(4):425-35. Epub 2010/04/27.
37. Woo S, Pawaskar D, Jusko WJ. Methods of utilizing baseline values for indirect response models. J Pharmacokinet Pharmacodyn. 2009;36(5):381-405. Epub 2009/08/22.